1. Home
  2. GLW vs ARGX Comparison

GLW vs ARGX Comparison

Compare GLW & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLW
  • ARGX
  • Stock Information
  • Founded
  • GLW 1851
  • ARGX 2008
  • Country
  • GLW United States
  • ARGX Netherlands
  • Employees
  • GLW N/A
  • ARGX N/A
  • Industry
  • GLW Telecommunications Equipment
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • GLW Industrials
  • ARGX Health Care
  • Exchange
  • GLW Nasdaq
  • ARGX Nasdaq
  • Market Cap
  • GLW 44.4B
  • ARGX 39.6B
  • IPO Year
  • GLW N/A
  • ARGX 2017
  • Fundamental
  • Price
  • GLW $67.34
  • ARGX $706.87
  • Analyst Decision
  • GLW Buy
  • ARGX Strong Buy
  • Analyst Count
  • GLW 13
  • ARGX 18
  • Target Price
  • GLW $65.17
  • ARGX $758.59
  • AVG Volume (30 Days)
  • GLW 5.3M
  • ARGX 450.8K
  • Earning Date
  • GLW 07-29-2025
  • ARGX 07-31-2025
  • Dividend Yield
  • GLW 1.66%
  • ARGX N/A
  • EPS Growth
  • GLW 83.78
  • ARGX N/A
  • EPS
  • GLW 0.94
  • ARGX 18.75
  • Revenue
  • GLW $14,206,000,000.00
  • ARGX $3,120,821,000.00
  • Revenue This Year
  • GLW $20.17
  • ARGX $77.61
  • Revenue Next Year
  • GLW $7.85
  • ARGX $30.50
  • P/E Ratio
  • GLW $71.81
  • ARGX $33.35
  • Revenue Growth
  • GLW 14.63
  • ARGX 88.04
  • 52 Week Low
  • GLW $37.31
  • ARGX $510.06
  • 52 Week High
  • GLW $67.67
  • ARGX $708.09
  • Technical
  • Relative Strength Index (RSI)
  • GLW 78.13
  • ARGX 74.86
  • Support Level
  • GLW $63.37
  • ARGX $658.60
  • Resistance Level
  • GLW $65.95
  • ARGX $669.53
  • Average True Range (ATR)
  • GLW 1.05
  • ARGX 12.85
  • MACD
  • GLW -0.17
  • ARGX 2.22
  • Stochastic Oscillator
  • GLW 99.55
  • ARGX 98.05

About GLW Corning Incorporated

Corning is a leader in materials science, specializing in the production of glass, ceramics, and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: